Co-Founder, Paradigm Shift Therapeutics
Teresa Burgess, PhD has deep experience in biopharma drug research, development and leadership. Dr. Burgess began her career at Amgen in Mammalian Cell Biology and moved into the High Throughput Screening group. She later served >10 years as Director within Amgen’s Oncology Research organization, developing a breadth of technical expertise and leadership experience integrating drug discovery, target validation, IND-enabling preclinical studies, regulatory science and clinical trials across Amgen’s multi-modality drug platforms. Dr. Burgess co-founded Paradigm Shift Therapeutics (PSTx) in Jan. 2014 to identify drug candidates with the potential to enhance immune surveillance. PSTx received seed and continuing funding from the Avon Foundation (2014-2019) and recently a federal grant from the NCI (2018-2021).
Her professional experience also includes service as Chair and Vice Chair for the California Breast Cancer Research Program (CBCRP); ad hoc reviewing for the Congressionally Directed Medical Research Program for Breast Cancer (CDMRP, informally referred to as the DoD BCRP) as well as participating in peer review for several cancer journals. She has been active in educational and mentoring programs at the local, and state levels throughout her career. Dr. Burgess obtained her BA from Berkeley, her PhD from UC San Francisco and was a Helen Hay Whitney postdoctoral fellow at UC Santa Barbara.Return to Leadership